Bullish
Abbott Laboratories (NYSE:ABT) has secured CE Mark for its new Libre Duo and Libre Duo 10 Day systems, which are the world's first dual glucose-ketone...
Neutral
This article provides a DCF analysis for Abbott Laboratories (ABT), comparing its intrinsic value against its current price of $90.50. The earnings-ba...
Neutral
Goldman Sachs has reaffirmed its "Buy" rating on Abbott Laboratories (ABT), although it slightly reduced the price target to $113 from $121. Analyst D...
Bullish
New research from Abbott's Healthy Food Rx "Food is Medicine" program, combined with community health worker coaching, shows significant health improv...
Abbott Laboratories (ABT) recently received CE Mark approval in Europe for its Libre Duo and Libre Duo 10 Day dual glucose-ketone continuous monitorin...
Bullish
Abbott announced new clinical data at ADA 2026 highlighting the increasing challenge of managing diabetic ketoacidosis (DKA) across all age groups wit...
Neutral
New data from Abbott reveals a significant rise in diabetic ketoacidosis (DKA) hospitalizations across all age groups, with nearly 60% of pediatric di...
Neutral
Abbott Laboratories is facing a proposed class-action lawsuit after a federal judge ruled that consumers could reasonably interpret the marketing for ...
This article identifies that the provided content for parsing is empty. Therefore, no summary can be generated about Abbott Laboratories. The article ...
Neutral
Jim Cramer highlighted Abbott Laboratories (NYSE:ABT) as a "legendary growth company" despite its stock trading at a lower multiple and price compared...
Bullish
Abbott Laboratories (ABT) has experienced a significant 33% share price slide over the past year, prompting an analysis of its current valuation. Usin...
Bearish
A former senior district sales manager has accused Abbott Laboratories Inc. of violating the False Claims Act by retaliating against him. Krishnan Gho...
Bullish
Abbott Laboratories' stock (ABT) is stabilizing after its recent inclusion in the Schwab U.S. Dividend Equity ETF (SCHD) and amidst varied institution...
Neutral
This article focuses on Abbott Laboratories (US0028241000) and its continued active listing on the NYSE as of May 30, 2026. The main point of interest...
Bullish
Abbott Laboratories has received European approval to market the world's first dual glucose-ketone sensor. This approval allows Abbott to introduce an...
Bullish
Abbott has received a CE mark for its Libre Duo and Libre Duo 10 Day continuous glucose-ketone monitoring systems, making them the first of their kind...
Neutral
Abbott Laboratories has settled a proposed class-action lawsuit under Illinois's Genetic Information Privacy Act. The lawsuit was brought by Quentin N...
Bullish
Abbott Laboratories (ABT) has received CE Mark approval for its new Libre Duo system, the first dual glucose-ketone monitoring technology globally. Th...
Bullish
Abbott has received CE mark approval for its Libre Duo dual glucose-ketone sensing technology for people with diabetes, marking a world first. This in...
Neutral
Abbott has received CE Mark approval for its Libre Duo and Libre Duo 10 Day continuous glucose-ketone sensing systems, marking the world's first dual ...